{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:00:23Z","timestamp":1785506423887,"version":"3.56.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":112,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-026-01550-5","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T18:55:59Z","timestamp":1775847359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Discovery of potent kinase inhibitors with improved pharmacokinetics and safety potentials through structural optimization of dasatinib"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7340-6946","authenticated-orcid":false,"given":"Kan","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lining","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"1550_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/cid\/cis353","volume":"55","author":"JG Pasipanodya","year":"2012","unstructured":"Pasipanodya, J. G., Srivastava, S. & Gumbo, T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 55, 169\u2013177 (2012).","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"1550_CR2","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1124\/dmd.32.6.639","volume":"32","author":"K He","year":"2004","unstructured":"He, K. et al. Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved. Drug Metab. Dispos. Biol. Fate Chem. 32, 639\u2013646 (2004).","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"1550_CR3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2165\/00003495-199855020-00012","volume":"55","author":"A Markham","year":"1998","unstructured":"Markham, A. & Wagstaff, A. J. Fexofenadine. Drugs 55, 269\u2013274 (1998). discussion 275-266.","journal-title":"Drugs"},{"key":"1550_CR4","first-page":"549","volume":"45","author":"EJ Murphy","year":"2000","unstructured":"Murphy, E. J. et al. Troglitazone-induced fulminant hepatic failure. Acute Liver Fail. Study Group. Dig. Dis. Sci. 45, 549\u2013553 (2000).","journal-title":"Acute Liver Fail. Study Group. Dig. Dis. Sci."},{"key":"1550_CR5","first-page":"1089","volume":"40","author":"FS Yen","year":"2020","unstructured":"Yen, F. S. et al. Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes. Liver Int. Off. J. Int. Assoc. Study Liver 40, 1089\u20131097 (2020).","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"1550_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","volume":"19","author":"M Schachter","year":"2005","unstructured":"Schachter, M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol. 19, 117\u2013125 (2005).","journal-title":"Fundam. Clin. Pharmacol."},{"key":"1550_CR7","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1053\/j.seminoncol.2011.01.016","volume":"38","author":"JY Blay","year":"2011","unstructured":"Blay, J. Y. & von Mehren, M. Nilotinib: a novel, selective tyrosine kinase inhibitor. Semin. Oncol. 38, S3\u2013S9 (2011).","journal-title":"Semin. Oncol."},{"key":"1550_CR8","doi-asserted-by":"publisher","first-page":"6819","DOI":"10.1021\/jm060727j","volume":"49","author":"J Das","year":"2006","unstructured":"Das, J. et al. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J. Med. Chem. 49, 6819\u20136832 (2006).","journal-title":"J. Med. Chem."},{"key":"1550_CR9","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo, L. J. et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658\u20136661 (2004).","journal-title":"J. Med. Chem."},{"key":"1550_CR10","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","volume":"66","author":"JS Tokarski","year":"2006","unstructured":"Tokarski, J. S. et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 66, 5790\u20135797 (2006).","journal-title":"Cancer Res."},{"key":"1550_CR11","doi-asserted-by":"publisher","first-page":"13283","DOI":"10.1073\/pnas.0702654104","volume":"104","author":"O Hantschel","year":"2007","unstructured":"Hantschel, O. et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc. Natl. Acad. Sci. USA 104, 13283\u201313288 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1550_CR12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrc3702","volume":"14","author":"RW Hendriks","year":"2014","unstructured":"Hendriks, R. W., Yuvaraj, S. & Kil, L. P. Targeting Bruton\u2019s tyrosine kinase in B cell malignancies. Nat. Rev. Cancer 14, 219\u2013232 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"1550_CR13","doi-asserted-by":"publisher","first-page":"16981","DOI":"10.1073\/pnas.1905239116","volume":"116","author":"C Scuoppo","year":"2019","unstructured":"Scuoppo, C. et al. Repurposing dasatinib for diffuse large B cell lymphoma. Proc. Natl. Acad. Sci. USA 116, 16981\u201316986 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1550_CR14","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1158\/0008-5472.CAN-19-2787","volume":"80","author":"TB Nguyen","year":"2020","unstructured":"Nguyen, T. B. et al. Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma. Cancer Res. 80, 1875\u20131884 (2020).","journal-title":"Cancer Res."},{"key":"1550_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-02764-y","volume":"19","author":"L Ntari","year":"2021","unstructured":"Ntari, L. et al. Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment. J. Transl. Med. 19, 165 (2021).","journal-title":"J. Transl. Med."},{"key":"1550_CR16","doi-asserted-by":"publisher","unstructured":"Leclercq, G. et al. Src\/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies. J. Immunother. Cancer 9, https:\/\/doi.org\/10.1136\/jitc-2021-002582 (2021).","DOI":"10.1136\/jitc-2021-002582"},{"key":"1550_CR17","doi-asserted-by":"publisher","unstructured":"Mestermann, K. et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells. Sci. Transl. Med. 11, https:\/\/doi.org\/10.1126\/scitranslmed.aau5907 (2019).","DOI":"10.1126\/scitranslmed.aau5907"},{"key":"1550_CR18","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.3389\/fimmu.2018.03133","volume":"9","author":"K Guo","year":"2018","unstructured":"Guo, K. et al. TreatmEnt Effects Of The Second-generation Tyrosine Kinase Inhibitor Dasatinib On Autoimmune Arthritis. Front. Immunol. 9, 3133 (2018).","journal-title":"Front. Immunol."},{"key":"1550_CR19","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-10-2616","volume":"17","author":"JC Montero","year":"2011","unstructured":"Montero, J. C., Seoane, S., Oca\u00f1a, A. & Pandiella, A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 17, 5546\u20135552 (2011).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"1550_CR20","doi-asserted-by":"publisher","unstructured":"Redin, E. et al. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation. J. Immunother. Cancer 9, https:\/\/doi.org\/10.1136\/jitc-2020-001496 (2021).","DOI":"10.1136\/jitc-2020-001496"},{"key":"1550_CR21","doi-asserted-by":"publisher","unstructured":"Zhao, J. et al. Senolytics cocktail dasatinib and quercetin alleviate chondrocyte senescence and facet joint osteoarthritis in mice. Spine J. Off. J. N. Am. Spine Soc., https:\/\/doi.org\/10.1016\/j.spinee.2024.09.017 (2024).","DOI":"10.1016\/j.spinee.2024.09.017"},{"key":"1550_CR22","doi-asserted-by":"publisher","unstructured":"Maurer, S., Kirsch, V., Ruths, L., Brenner, R. E. & Riegger, J. Senolytic therapy combining Dasatinib and Quercetin restores the chondrogenic phenotype of human osteoarthritic chondrocytes by the release of pro-anabolic mediators. Aging Cell, e14361, https:\/\/doi.org\/10.1111\/acel.14361 (2024).","DOI":"10.1111\/acel.14361"},{"key":"1550_CR23","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.18632\/aging.205581","volume":"16","author":"E Lee","year":"2024","unstructured":"Lee, E. et al. Exploring the effects of Dasatinib, Quercetin, and Fisetin on DNA methylation clocks: a longitudinal study on senolytic interventions. Aging 16, 3088\u20133106 (2024).","journal-title":"Aging"},{"key":"1550_CR24","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1007\/s11357-023-00830-5","volume":"45","author":"AD Ruggiero","year":"2023","unstructured":"Ruggiero, A. D. et al. Long-term dasatinib plus quercetin effects on aging outcomes and inflammation in nonhuman primates: implications for senolytic clinical trial design. GeroScience 45, 2785\u20132803 (2023).","journal-title":"GeroScience"},{"key":"1550_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104481","volume":"90","author":"A Nambiar","year":"2023","unstructured":"Nambiar, A. et al. Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability. EBioMedicine 90, 104481 (2023).","journal-title":"EBioMedicine"},{"key":"1550_CR26","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/14756366.2021.1995379","volume":"37","author":"MA Zaafan","year":"2022","unstructured":"Zaafan, M. A. & Abdelhamid, A. M. Dasatinib ameliorates thioacetamide-induced liver fibrosis: modulation of miR-378 and miR-17 and their linked Wnt\/beta-catenin and TGF-beta\/smads pathways. J. Enzym. Inhib. Med. Chem. 37, 118\u2013124 (2022).","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"1550_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/jfbc.14471","volume":"46","author":"KS Alharbi","year":"2022","unstructured":"Alharbi, K. S. et al. A study of the molecular mechanism of quercetin and dasatinib combination as senolytic in alleviating age-related and kidney diseases. J. Food Biochem. 46, e14471 (2022).","journal-title":"J. Food Biochem."},{"key":"1550_CR28","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1016\/j.mayocp.2021.06.025","volume":"96","author":"O Salaami","year":"2021","unstructured":"Salaami, O. et al. Antidiabetic effects of the senolytic agent dasatinib. Mayo Clin. Proc. 96, 3021\u20133029 (2021).","journal-title":"Mayo Clin. Proc."},{"key":"1550_CR29","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/gerona\/glab002","volume":"76","author":"TD Saccon","year":"2021","unstructured":"Saccon, T. D. et al. Senolytic combination of dasatinib and quercetin alleviates intestinal senescence and inflammation and modulates the gut microbiome in aged mice.  J. Gerontol. Ser. A Biol. Sci. Med. Sci. 76, 1895\u20131905 (2021).","journal-title":"J. Gerontol. Ser. A Biol. Sci. Med. Sci."},{"key":"1550_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25453-2","volume":"12","author":"EJ Novais","year":"2021","unstructured":"Novais, E. J. et al. Long-term treatment with senolytic drugs Dasatinib and Quercetin ameliorates age-dependent intervertebral disc degeneration in mice. Nat. Commun. 12, 5213 (2021).","journal-title":"Nat. Commun."},{"key":"1550_CR31","doi-asserted-by":"publisher","unstructured":"Anerillas, C., Herman, A. B., Rossi, M., Munk, R. & Lehrmann, E. Early SRC activation skews cell fate from apoptosis to senescence. 8, eabm0756, https:\/\/doi.org\/10.1126\/sciadv.abm0756 (2022).","DOI":"10.1126\/sciadv.abm0756"},{"key":"1550_CR32","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/acel.12344","volume":"14","author":"Y Zhu","year":"2015","unstructured":"Zhu, Y. et al. The Achilles\u2019 heel of senescent cells: from transcriptome to senolytic drugs. Aging cell 14, 644\u2013658 (2015).","journal-title":"Aging cell"},{"key":"1550_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.105115","volume":"299","author":"Y Kim","year":"2023","unstructured":"Kim, Y., Ahmed, S. & Miller, W. T. Colorectal cancer-associated mutations impair EphB1 kinase function.  J. Biol. Chem. 299, 105115 (2023).","journal-title":"J. Biol. Chem."},{"key":"1550_CR34","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/sj.bjc.6604676","volume":"99","author":"Q Chang","year":"2008","unstructured":"Chang, Q., Jorgensen, C., Pawson, T. & Hedley, D. W. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br. J. Cancer 99, 1074\u20131082 (2008).","journal-title":"Br. J. Cancer"},{"key":"1550_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1756-8722-5-23","volume":"5","author":"N Takahashi","year":"2012","unstructured":"Takahashi, N., Miura, M., Scott, S. A., Niioka, T. & Sawada, K. Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation. J. Hematol. Oncol. 5, 23 (2012).","journal-title":"J. Hematol. Oncol."},{"key":"1550_CR36","doi-asserted-by":"publisher","first-page":"6232","DOI":"10.1158\/1078-0432.CCR-09-0224","volume":"15","author":"GD Demetri","year":"2009","unstructured":"Demetri, G. D. et al. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 15, 6232\u20136240 (2009).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"1550_CR37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00277-017-3144-1","volume":"97","author":"A Iurlo","year":"2018","unstructured":"Iurlo, A. et al. Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. Ann. Hematol. 97, 95\u2013100 (2018).","journal-title":"Ann. Hematol."},{"key":"1550_CR38","first-page":"85","volume":"5","author":"X Wang","year":"2013","unstructured":"Wang, X. et al. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. Clin. Pharmacol. Adv. Appl. 5, 85\u201397 (2013).","journal-title":"Clin. Pharmacol. Adv. Appl."},{"key":"1550_CR39","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/cncr.24734","volume":"116","author":"K Porkka","year":"2010","unstructured":"Porkka, K. et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 116, 377\u2013386 (2010).","journal-title":"Cancer"},{"key":"1550_CR40","doi-asserted-by":"publisher","unstructured":"Weatherald, J., Bondeelle, L., Chaumais, M. C. & Guignabert, C. Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. 56, https:\/\/doi.org\/10.1183\/13993003.00279-2020 (2020).","DOI":"10.1183\/13993003.00279-2020"},{"key":"1550_CR41","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s12185-011-0921-9","volume":"94","author":"D Kim","year":"2011","unstructured":"Kim, D., Goh, H. G., Kim, S. H., Cho, B. S. & Kim, D. W. Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy. Int. J. Hematol. 94, 361\u2013371 (2011).","journal-title":"Int. J. Hematol."},{"key":"1550_CR42","doi-asserted-by":"publisher","first-page":"E224","DOI":"10.1002\/ajh.24194","volume":"90","author":"M Tatarczuch","year":"2015","unstructured":"Tatarczuch, M., Burbury, K., Creati, L., Januszewicz, E. H. & Seymour, J. F. Dasatinib therapy can result in significant pulmonary toxicity. Am. J. Hematol. 90, E224\u2013E225 (2015).","journal-title":"Am. J. Hematol."},{"key":"1550_CR43","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1183\/13993003.01410-2016","volume":"48","author":"M Riou","year":"2016","unstructured":"Riou, M. et al. Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity.  Eur. Respir. J. 48, 1517\u20131519 (2016).","journal-title":"Eur. Respir. J."},{"key":"1550_CR44","doi-asserted-by":"publisher","unstructured":"Weatherald, J. et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. Eur. Respir. J. 50, https:\/\/doi.org\/10.1183\/13993003.00217-2017 (2017).","DOI":"10.1183\/13993003.00217-2017"},{"key":"1550_CR45","doi-asserted-by":"publisher","first-page":"673","DOI":"10.21037\/tp-23-517","volume":"13","author":"W Zhao","year":"2024","unstructured":"Zhao, W., Wang, K., Yu, L., Guo, Y. & Li, Z. Dasatinib-induced pleural effusions, pericardial effusion and pulmonary arterial hypertension: a case report. Transl. Pediatr. 13, 673\u2013681 (2024).","journal-title":"Transl. Pediatr."},{"key":"1550_CR46","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","volume":"25","author":"A Quint\u00e1s-Cardama","year":"2007","unstructured":"Quint\u00e1s-Cardama, A. et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 25, 3908\u20133914 (2007).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"1550_CR47","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1124\/dmd.107.018267","volume":"36","author":"LJ Christopher","year":"2008","unstructured":"Christopher, L. J. et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab. Dispos. Biol. Fate Chem. 36, 1357\u20131364 (2008).","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"1550_CR48","doi-asserted-by":"publisher","first-page":"W422","DOI":"10.1093\/nar\/gkae236","volume":"52","author":"L Fu","year":"2024","unstructured":"Fu, L. et al. ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support. Nucleic Acids Res. 52, W422\u2013W431 (2024).","journal-title":"Nucleic Acids Res."},{"key":"1550_CR49","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621\u2013681 (2006).","journal-title":"Pharmacol. Rev."},{"key":"1550_CR50","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/S0090-9556(24)14938-0","volume":"27","author":"RS Obach","year":"1999","unstructured":"Obach, R. S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. Biol. Fate Chem. 27, 1350\u20131359 (1999).","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"1550_CR51","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1124\/dmd.107.018234","volume":"36","author":"LJ Christopher","year":"2008","unstructured":"Christopher, L. J. et al. Biotransformation of [14C]dasatinib: in vitro studies in rat, monkey, and human and disposition after administration to rats and monkeys. Drug Metab. Dispos. Biol. Fate Chem. 36, 1341\u20131356 (2008).","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"1550_CR52","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang, W. et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D955\u2013D961 (2013).","journal-title":"Nucleic Acids Res."},{"key":"1550_CR53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2014.06.023","volume":"26","author":"RM Young","year":"2014","unstructured":"Young, R. M. & Staudt, L. M. Ibrutinib treatment of CLL: the cancer fights back. Cancer Cell 26, 11\u201313 (2014).","journal-title":"Cancer Cell"},{"key":"1550_CR54","doi-asserted-by":"crossref","unstructured":"Reiff, S. D. et al. The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter Transformation. Cancer Discov. 8, 1300\u20131315, (2018).","DOI":"10.1158\/2159-8290.CD-17-1409"},{"key":"1550_CR55","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/bjh.15702","volume":"184","author":"JM Umakanthan","year":"2019","unstructured":"Umakanthan, J. M. et al. Phase I\/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma. Br. J. Haematol. 184, 744\u2013752 (2019).","journal-title":"Br. J. Haematol."},{"key":"1550_CR56","doi-asserted-by":"crossref","unstructured":"Akre, M. K., Mitra, A. & Wang, W. Development of expression-based biomarkers of Dasatinib response in hematologic malignancies. Blood Cancer J. 7, 652, (2017).","DOI":"10.1038\/s41408-017-0013-z"},{"key":"1550_CR57","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.ebiom.2018.12.052","volume":"40","author":"JN Justice","year":"2019","unstructured":"Justice, J. N. et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine 40, 554\u2013563 (2019).","journal-title":"EBioMedicine"},{"key":"1550_CR58","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ebiom.2019.08.069","volume":"47","author":"LJ Hickson","year":"2019","unstructured":"Hickson, L. J. et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine 47, 446\u2013456 (2019).","journal-title":"EBioMedicine"},{"key":"1550_CR59","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00280-007-0478-8","volume":"61","author":"AV Kamath","year":"2008","unstructured":"Kamath, A. V., Wang, J., Lee, F. Y. & Marathe, P. H. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother. Pharmacol. 61, 365\u2013376 (2008).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"1550_CR60","doi-asserted-by":"crossref","unstructured":"He, K. in Overcoming Obstacles in Drug Discovery and Development: Surmounting the Insurmountable - Case Studies for Critical Thinking (ed He, K., Hollenberg, P. F. & Wienkers, L. C.) Ch. 9, 123 (Elsevier, 2023).","DOI":"10.1016\/B978-0-12-817134-9.00023-4"},{"key":"1550_CR61","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","volume":"12","author":"D Sun","year":"2022","unstructured":"Sun, D., Gao, W., Hu, H. & Zhou, S. Why 90% of clinical drug development fails and how to improve it? Acta Pharm. Sin. B 12, 3049\u20133062 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"1550_CR62","doi-asserted-by":"publisher","first-page":"4140","DOI":"10.1182\/blood-2013-03-491423","volume":"122","author":"J Han","year":"2013","unstructured":"Han, J. et al. A critical role for Lyn kinase in strengthening endothelial integrity and barrier function. Blood 122, 4140\u20134149 (2013).","journal-title":"Blood"},{"key":"1550_CR63","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1172\/JCI86249","volume":"126","author":"C Guignabert","year":"2016","unstructured":"Guignabert, C. et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.  J. Clin. Investig. 126, 3207\u20133218 (2016).","journal-title":"J. Clin. Investig."},{"key":"1550_CR64","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/bja\/aeg117","volume":"91","author":"F Boer","year":"2003","unstructured":"Boer, F. Drug handling by the lungs. Br. J. Anaesth. 91, 50\u201360 (2003).","journal-title":"Br. J. Anaesth."},{"key":"1550_CR65","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1046\/j.1440-1681.1999.03048.x","volume":"26","author":"RN Upton","year":"1999","unstructured":"Upton, R. N. & Doolette, D. J. Kinetic aspects of drug disposition in the lungs. Clin. Exp. Pharmacol. Physiol. 26, 381\u2013391 (1999).","journal-title":"Clin. Exp. Pharmacol. Physiol."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01550-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01550-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01550-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T13:02:57Z","timestamp":1785502977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01550-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1550"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01550-5","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"16 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.H. and L.C. are employees of Princeton Drug Discovery Inc. and may hold equity in the company. In addition, K.H. is the inventor on patents related to the new chemical entities described in this manuscript. All other authors declare no competing financial or non-financial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"423"}}